TY - JOUR AU - Robert, C. AU - Long, G. V. AU - Brady, B. AU - Dutriaux, C. AU - Maio, M. AU - Mortier, L. PY - 2015 DA - 2015// TI - Nivolumab in previously untreated melanoma without BRAF mutation JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1412082 DO - 10.1056/NEJMoa1412082 ID - Robert2015 ER - TY - JOUR AU - Hodi, F. S. AU - O’Day, S. J. AU - McDermott, D. F. AU - Weber, R. W. AU - Sosman, J. A. AU - Haanen, J. B. PY - 2010 DA - 2010// TI - Improved survival with ipilimumab in patients with metastatic melanoma JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1003466 DO - 10.1056/NEJMoa1003466 ID - Hodi2010 ER - TY - JOUR AU - Chapman, P. B. AU - Hauschild, A. AU - Robert, C. AU - Haanen, J. B. AU - Ascierto, P. AU - Larkin, J. PY - 2011 DA - 2011// TI - Improved survival with vemurafenib in melanoma with BRAF V600E mutation JO - N Engl J Med VL - 364 UR - https://doi.org/10.1056/NEJMoa1103782 DO - 10.1056/NEJMoa1103782 ID - Chapman2011 ER - TY - JOUR AU - Naidoo, J. AU - Page, D. B. AU - Li, B. T. AU - Connell, L. C. AU - Schindler, K. AU - Lacouture, M. E. PY - 2015 DA - 2015// TI - Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies JO - Ann Oncol VL - 26 ID - Naidoo2015 ER - TY - JOUR AU - Weber, J. S. AU - Kahler, K. C. AU - Hauschild, A. PY - 2012 DA - 2012// TI - Management of immune-related adverse events and kinetics of response with ipilimumab JO - J Clin Oncol VL - 30 UR - https://doi.org/10.1200/JCO.2012.41.6750 DO - 10.1200/JCO.2012.41.6750 ID - Weber2012 ER - TY - JOUR AU - Lacouture, M. E. AU - Wolchok, J. D. AU - Yosipovitch, G. AU - Kahler, K. C. AU - Busam, K. J. AU - Hauschild, A. PY - 2014 DA - 2014// TI - Ipilimumab in patients with cancer and the management of dermatologic adverse events JO - J Am Acad Dermatol VL - 71 UR - https://doi.org/10.1016/j.jaad.2014.02.035 DO - 10.1016/j.jaad.2014.02.035 ID - Lacouture2014 ER - TY - STD TI - Tarhini A. Immune-mediated adverse events associated with ipilimumab ctla-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica (Cairo). 2013;2013:857519. doi:10.1155/2013/857519. ID - ref7 ER - TY - JOUR AU - Hodi, F. S. AU - Butler, M. AU - Oble, D. A. AU - Seiden, M. V. AU - Haluska, F. G. AU - Kruse, A. PY - 2008 DA - 2008// TI - Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients JO - Proc Natl Acad Sci U S A VL - 105 UR - https://doi.org/10.1073/pnas.0712237105 DO - 10.1073/pnas.0712237105 ID - Hodi2008 ER - TY - JOUR AU - Weaver, J. AU - Bergfeld, W. F. PY - 2009 DA - 2009// TI - Grover disease (transient acantholytic dermatosis) JO - Arch Pathol Lab Med VL - 133 ID - Weaver2009 ER - TY - JOUR AU - Desch, J. K. AU - Smoller, B. R. PY - 1993 DA - 1993// TI - The spectrum of cutaneous disease in leukemias JO - J Cutan Pathol VL - 20 UR - https://doi.org/10.1111/j.1600-0560.1993.tb00662.x DO - 10.1111/j.1600-0560.1993.tb00662.x ID - Desch1993 ER - TY - JOUR AU - Davis, M. D. AU - Dinneen, A. M. AU - Landa, N. AU - Gibson, L. E. PY - 1999 DA - 1999// TI - Grover’s disease: clinicopathologic review of 72 cases JO - Mayo Clin Proc VL - 74 UR - https://doi.org/10.4065/74.3.229 DO - 10.4065/74.3.229 ID - Davis1999 ER - TY - JOUR AU - Zvulunov, A. AU - Grunwald, M. H. AU - Avinoach, I. AU - Halevy, S. PY - 1997 DA - 1997// TI - Transient acantholytic dermatosis (Grover’s disease) in a patient with progressive systemic sclerosis treated with D-penicillamine JO - Int J Dermatol VL - 36 UR - https://doi.org/10.1111/j.1365-4362.1997.tb01138.x DO - 10.1111/j.1365-4362.1997.tb01138.x ID - Zvulunov1997 ER - TY - JOUR AU - Mahler, S. J. AU - Villez, R. L. AU - Pulitzer, D. R. PY - 1993 DA - 1993// TI - Transient acantholytic dermatosis induced by recombinant human interleukin 4 JO - J Am Acad Dermatol VL - 29 UR - https://doi.org/10.1016/0190-9622(93)70169-T DO - 10.1016/0190-9622(93)70169-T ID - Mahler1993 ER - TY - JOUR AU - Eisenhauer, E. A. AU - Therasse, P. AU - Bogaerts, J. AU - Schwartz, L. H. AU - Sargent, D. AU - Ford, R. PY - 2009 DA - 2009// TI - New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauer2009 ER - TY - JOUR AU - Chu, E. Y. AU - Wanat, K. A. AU - Miller, C. J. AU - Amaravadi, R. K. AU - Fecher, L. A. AU - Brose, M. S. PY - 2012 DA - 2012// TI - Diverse cutaneous side effects associated with BRAF inhibitor therapy: a clinicopathologic study JO - J Am Acad Dermatol VL - 67 UR - https://doi.org/10.1016/j.jaad.2012.04.008 DO - 10.1016/j.jaad.2012.04.008 ID - Chu2012 ER - TY - JOUR AU - Anforth, R. M. AU - Blumetti, T. C. AU - Kefford, R. F. AU - Sharma, R. AU - Scolyer, R. A. AU - Kossard, S. PY - 2012 DA - 2012// TI - Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma JO - Br J Dermatol VL - 167 UR - https://doi.org/10.1111/j.1365-2133.2012.11155.x DO - 10.1111/j.1365-2133.2012.11155.x ID - Anforth2012 ER - TY - JOUR AU - Carlos, G. AU - Anforth, R. AU - Chou, S. AU - Clements, A. AU - Fernandez-Penas, P. PY - 2015 DA - 2015// TI - A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab JO - Melanoma Res VL - 25 UR - https://doi.org/10.1097/CMR.0000000000000155 DO - 10.1097/CMR.0000000000000155 ID - Carlos2015 ER - TY - JOUR AU - Munoz, J. AU - Guillot, B. AU - Girard, C. AU - Dereure, O. AU - Du-Thanh, A. PY - 2014 DA - 2014// TI - First report of ipilimumab-induced Grover disease JO - Br J Dermatol VL - 171 UR - https://doi.org/10.1111/bjd.13058 DO - 10.1111/bjd.13058 ID - Munoz2014 ER -